T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) – Pipeline Review, H1 2018’, provides in depth analysis on T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Immunology, Central Nervous System, Infectious Disease and Musculoskeletal Disorders under development targeting T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)

– The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects

– The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc

Celgene Corp

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

MacroGenics Inc

Meridigen Biotech Co Ltd

Numab Innovation AG

SYNIMMUNE GmbH

Tiziana Life Sciences Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) Overview

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) Companies Involved in Therapeutics Development

Amgen Inc

Celgene Corp

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

MacroGenics Inc

Meridigen Biotech Co Ltd

Numab Innovation AG

SYNIMMUNE GmbH

Tiziana Life Sciences Plc

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) Drug Profiles

AMG-330 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVA-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target CD3E and PSMA for Prostate Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

blinatumomab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coltelizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EM-801 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

foralumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-007 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

otelixizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasotuxizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-6026 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-7082859 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TACSYN Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teplizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-13551 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) Dormant Products

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) Product Development Milestones

Featured News & Press Releases

Jan 09, 2018: Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE) Antibody Construct Blinatumomab for Relapsed or Refractory B- cell Precursor Acute Lymphoblastic Leukemia in Japan

Sep 06, 2017: Development of a Proprietary Oral Formulation of Foralumab, a Fully Human Anti-CD3 mAb, for use in an Upcoming Phase 2a Clinical Trial in NASH

Jul 28, 2017: Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases

Jul 11, 2017: FDA Grants Full Approval for BLINCYTO (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children

Jun 23, 2017: European Hematology Association: The More the T-lymphocytes Differ, the More Effectively They Fight Against Leukemia

Jun 21, 2017: Amgen To Present Data on BLINCYTO At 22nd Congress of the European Hematology Association

Jun 02, 2017: City of Hope Presents Study Results of Blinatumomab at 2017 American Society of Clinical Oncology meeting

Mar 29, 2017: FDA Grants Priority Review For Amgen's BLINCYTO (blinatumomab) Supplemental Biologics License Application

Mar 29, 2017: Journal Of Clinical Oncology Publishes Data On BLINCYTO (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

Mar 14, 2017: Tiziana Life Sciences Appoints Dr. Arun Sanyal to its Scientific Advisory Board

Mar 01, 2017: BLINCYTO (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy

Feb 14, 2017: Amgen Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Nov 30, 2016: Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia At ASH 2016

Nov 18, 2016: New Publication: Partial Exhaustion of CD8 T Cells in Responders to Anti-CD3 Treatment in New-Onset Type 1 Diabetes

Nov 16, 2016: Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by Celgene Corp, H1 2018

Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Pipeline by GlaxoSmithKline Plc, H1 2018

Pipeline by MacroGenics Inc, H1 2018

Pipeline by Meridigen Biotech Co Ltd, H1 2018

Pipeline by Numab Innovation AG, H1 2018

Pipeline by SYNIMMUNE GmbH, H1 2018

Pipeline by Tiziana Life Sciences Plc, H1 2018

Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports